BACKGROUND: Few epidemiologic studies have investigated the use of venlafaxine (Effexor XR capsules, Product Monograph, Wyeth, Montreal, Canada), an antidepressant used to treat major depression and anxiety disorders in adults, during pregnancy. Our objective was to determine whether use of venlafaxine during pregnancy is associated with specific birth defects. METHODS: We used data from the National Birth Defects Prevention Study (NBDPS), a population-based, case-control study in the United States. Our analysis included mothers with pregnancies affected by one of 30 selected birth defects (cases) and babies without birth defects (controls) with estimated dates of delivery between 1997 and 2007. Exposure was any reported use of venlafaxine from 1 month preconception through the third month of pregnancy. We calculated adjusted odds ratios (aORs) and 95% Fisher Exact confidence intervals (CIs) for 24 birth defect groups for which at least 400 case mothers were interviewed. Our adjusted analyses controlled for maternal age and race/ethnicity. RESULTS: Among the 27,045 NBDPS participants who met inclusion criteria, 0.17% (14/8002) of control mothers and 0.40% (77/19,043) of case mothers reported any use of venlafaxine from 1 month preconception through the third month of pregnancy. Statistically significant associations were found for anencephaly, atrial septal defect (ASD) secundum, or ASD not otherwise specified, coarctation of the aorta, cleft palate, and gastroschisis. CONCLUSIONS: Our data suggest associations between periconceptional use of venlafaxine and some birth defects. However, sample sizes were small, CIs were wide, and additional studies are needed to confirm these results.
BACKGROUND: Few epidemiologic studies have investigated the use of venlafaxine (Effexor XR capsules, Product Monograph, Wyeth, Montreal, Canada), an antidepressant used to treat major depression and anxiety disorders in adults, during pregnancy. Our objective was to determine whether use of venlafaxine during pregnancy is associated with specific birth defects. METHODS: We used data from the National Birth Defects Prevention Study (NBDPS), a population-based, case-control study in the United States. Our analysis included mothers with pregnancies affected by one of 30 selected birth defects (cases) and babies without birth defects (controls) with estimated dates of delivery between 1997 and 2007. Exposure was any reported use of venlafaxine from 1 month preconception through the third month of pregnancy. We calculated adjusted odds ratios (aORs) and 95% Fisher Exact confidence intervals (CIs) for 24 birth defect groups for which at least 400 case mothers were interviewed. Our adjusted analyses controlled for maternal age and race/ethnicity. RESULTS: Among the 27,045 NBDPS participants who met inclusion criteria, 0.17% (14/8002) of control mothers and 0.40% (77/19,043) of case mothers reported any use of venlafaxine from 1 month preconception through the third month of pregnancy. Statistically significant associations were found for anencephaly, atrial septal defect (ASD) secundum, or ASD not otherwise specified, coarctation of the aorta, cleft palate, and gastroschisis. CONCLUSIONS: Our data suggest associations between periconceptional use of venlafaxine and some birth defects. However, sample sizes were small, CIs were wide, and additional studies are needed to confirm these results.
Authors: Adrienne Einarson; Alessandra Pistelli; Marco DeSantis; Heli Malm; Wolfgang D Paulus; Alice Panchaud; Debra Kennedy; Thomas R Einarson; Gideon Koren Journal: Am J Psychiatry Date: 2008-04-01 Impact factor: 18.112
Authors: Tim F Oberlander; William Warburton; Shaila Misri; Wayne Riggs; Jaafar Aghajanian; Clyde Hertzman Journal: Birth Defects Res B Dev Reprod Toxicol Date: 2008-02
Authors: Susan E Andrade; Marsha A Raebel; Jeffrey Brown; Kimberly Lane; James Livingston; Denise Boudreau; Sharon J Rolnick; Douglas Roblin; David H Smith; Mary E Willy; Judy A Staffa; Richard Platt Journal: Am J Obstet Gynecol Date: 2007-10-01 Impact factor: 8.661
Authors: Sarah C Tinker; Suzan L Carmichael; Marlene Anderka; Marilyn L Browne; Kristin M Caspers Conway; Robert E Meyer; Wendy N Nembhard; Richard S Olney; Jennita Reefhuis Journal: Birth Defects Res A Clin Mol Teratol Date: 2015-04-06
Authors: Laura E Mitchell; A J Agopian; Angela Bhalla; Joseph T Glessner; Cecilia E Kim; Michael D Swartz; Hakon Hakonarson; Elizabeth Goldmuntz Journal: Hum Mol Genet Date: 2014-08-18 Impact factor: 6.150
Authors: Jennifer N Lind; Sarah C Tinker; Cheryl S Broussard; Jennita Reefhuis; Suzan L Carmichael; Margaret A Honein; Richard S Olney; Samantha E Parker; Martha M Werler Journal: Pharmacoepidemiol Drug Saf Date: 2013-04-26 Impact factor: 2.890